Posted by Michael Wonder on 16 Nov 2016
Amgen and Allergan submit biosimilar biologics license application for ABP 215 to U.S. FDA
15 November 2016 - Supported by phase 3 study in patients with non-squamous non-small-cell lung cancer.
Amgen and Allergan today announced the submission of a biologics license application to the U.S. FDA for ABP 215, a biosimilar candidate to Avastin (bevacizumab).
ABP 215 is the most advanced of the four oncology biosimilar medicines that Amgen and Allergan are collaborating on. The companies believe this submission is the first bevacizumab biosimilar application submitted to the FDA.
